ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 study (STOPDAPT-3)
Completed
- Conditions
- Ischemic heart disease, stable angina, myocardial infarction
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 6000
Inclusion Criteria
Patients who are planned to have PCI with exclusive use of EES (XienceTM series).
Patients with ARC-HBR or ACS
Patients who could take DAPT with aspirin and P2Y12 inhibitors for 1-month
Exclusion Criteria
Patients who withdraw consent (Included in the safety analysis set)
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method Major bleeding endpoint (BARC 3 or 5 bleeding) at 1-month (Superiority) 1-month Major bleeding endpoint (BARC 3 or 5 bleeding)
Cardiovascular composite endpoint: cardiovascular death, myocardial infarction (MI), ischemic stroke or definite stent thrombosis (ST) at 1-month (Non-inferiority) 1-month Cardiovascular composite endpoint: cardiovascular death, myocardial infarction (MI), ischemic stroke or definite stent thrombosis (ST)
- Secondary Outcome Measures
Name Time Method